Opportunity Information: Apply for PAR 22 194
The NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders opportunity (PAR 22-194) is a National Institutes of Health (NIH) grant mechanism designed to expand and strengthen the Trans-Omics for Precision Medicine (TOPMed) program by generating new, large-scale omics and phenotype datasets focused on heart, lung, blood, and sleep (HLBS) disorders. The main purpose is to help the field move beyond identifying genetic associations (the "map") and toward understanding how those associations actually cause disease (the "mechanism"), often described as a transition from Map to Mechanism (M2). In practical terms, the FOA is looking for projects that can produce integrated genetic and multi-omics data in areas where TOPMed’s existing resources do not yet provide enough coverage, depth, population diversity, disease representation, or relevant phenotypic detail to fully answer key biological questions.
A defining feature of this FOA is that it uses the X01 activity code and explicitly provides no direct funding to the applicant. Instead of supplying dollars for research expenses, the program primarily offers access to TOPMed-supported capabilities and infrastructure to generate omics data at scale, with the expectation that applicants bring well-phenotyped samples and strong scientific rationales for why new omics profiling would fill a major gap in current datasets. This structure is meant to accelerate community access to high-quality, standardized multi-omics resources by leveraging centralized TOPMed processes, rather than having many separate labs produce smaller, less harmonized datasets. The FOA also notes that clinical trials are not allowed, meaning applications must be focused on observational research, biospecimen-based analyses, data generation, and related discovery work rather than interventional human studies.
The work supported through this program centers on producing and integrating genetic and multi-omics information to clarify molecular pathways that contribute to HLBS conditions. While the FOA summary does not list every assay type, "multi-omics" in TOPMed contexts commonly refers to combinations of genome-wide sequencing or genotyping with other layers such as transcriptomics, epigenomics, proteomics, metabolomics, and other molecular phenotypes, paired with carefully curated clinical and physiological measurements. The emphasis on "omics phenotypes" signals that the program is not only interested in DNA sequence variation, but also in molecular readouts that sit between genes and disease traits, helping researchers identify causal mechanisms, regulatory effects, biomarkers, and potential therapeutic targets.
Another core expectation is broad data sharing. Omics outputs and the associated phenotypic data are intended to be deposited into NIH-designated controlled-access repositories, specifically calling out dbGaP (the Database of Genotypes and Phenotypes) and NHLBI’s BioData Catalyst (BDC). Controlled access means the data become widely available to qualified investigators under NIH data use and governance rules, helping maximize scientific return, promote reproducibility, and enable secondary analyses across studies. This also implies that applicants must be prepared for the consent, privacy, governance, and data harmonization requirements that come with generating datasets destined for public controlled-access distribution.
In terms of who can apply, eligibility is broad and spans many organization types. The FOA allows applications from state, county, city, township, and special district governments; public housing authorities; independent school districts; and a wide range of academic institutions including public and state-controlled universities, private institutions of higher education, and other research-performing organizations. It is also open to nonprofit organizations both with and without 501(c)(3) status, for-profit organizations (other than small businesses), and small businesses. Importantly, it highlights inclusion of institutions and organizations that expand participation across communities and geographies, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as tribal governments and tribal organizations, faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and even non-U.S. (foreign) entities. This breadth aligns with TOPMed’s broader goals of improving representation and ensuring that omics reference resources are relevant across diverse populations.
From an administrative standpoint, this is a discretionary NIH grant opportunity categorized under health research and linked to multiple CFDA numbers (93.233, 93.837, 93.838, 93.839, 93.840), reflecting NHLBI’s involvement across heart, lung, blood, and related research areas. The opportunity was created on June 1, 2022, and the listed closing date is October 17, 2024. While typical grant announcements include an award ceiling and expected number of awards, those fields are not specified here, and the most important operational detail remains that the FOA does not provide funds directly, instead supporting omics data generation and deposition through TOPMed program resources.
Overall, this FOA is best understood as an access pathway into the TOPMed data-generation ecosystem for investigators who have valuable cohorts, samples, and phenotypes relevant to HLBS disorders, and who can clearly justify how new multi-omics profiling would fill a meaningful gap in existing TOPMed datasets. The end product is not just a single-study dataset for the applicant, but a community resource that can power large-scale mechanism-focused discovery when combined with other TOPMed and NIH datasets in dbGaP and BioData Catalyst.Apply for PAR 22 194
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.233, 93.837, 93.838, 93.839, 93.840.
- This funding opportunity was created on 2022-06-01.
- Applicants must submit their applications by 2024-10-17. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: NHLBI TOPMed - Omics Phenotypes of Heart, Lung, and Blood Disorders (PAR 22-194)
What is this funding opportunity?
This opportunity is an NIH/NHLBI program intended to expand and strengthen the Trans-Omics for Precision Medicine (TOPMed) program by generating new, large-scale omics and phenotype datasets focused on heart, lung, blood, and sleep (HLBS) disorders.
What is the main goal of the FOA?
The main goal is to help research move from identifying genetic associations (the "map") to understanding how those associations contribute to disease (the "mechanism"). This is described as the Map to Mechanism (M2) transition.
What kinds of projects does it support?
Projects are expected to generate and integrate genetic and multi-omics data paired with well-curated phenotypic information for HLBS disorders, especially in areas where existing TOPMed resources lack sufficient coverage, depth, diversity, disease representation, or relevant phenotypic detail.
What does "omics phenotypes" mean in this context?
"Omics phenotypes" emphasizes molecular readouts that sit between genes and disease traits. The program is not limited to DNA sequence variation; it is also focused on molecular measurements that can clarify pathways, regulation, biomarkers, and potential therapeutic targets.
What does "multi-omics" generally refer to for TOPMed?
While the summary does not list every assay type, TOPMed multi-omics commonly involves combining genome-wide sequencing or genotyping with other layers such as transcriptomics, epigenomics, proteomics, metabolomics, and other molecular phenotypes, linked to carefully curated clinical and physiological measurements.
What research areas are in scope?
The scope centers on heart, lung, blood, and sleep (HLBS) disorders, with an emphasis on generating datasets that can clarify molecular pathways and disease mechanisms relevant to those conditions.
How is this opportunity different from typical NIH grants?
This FOA uses the X01 activity code and does not provide direct funding to the applicant. Instead of awarding dollars for research expenses, it provides access to TOPMed-supported capabilities and infrastructure to generate omics data at scale.
If there is no direct funding, what does the program provide?
Rather than paying research costs directly, the program primarily supports omics data generation through TOPMed resources and centralized processes, with the expectation that applicants contribute well-phenotyped samples and a strong rationale for new profiling.
What is expected from applicants?
Applicants are expected to bring well-phenotyped samples and a strong scientific justification showing how the proposed omics profiling would fill a major gap in existing TOPMed datasets (for example, gaps in population diversity, disease representation, phenotypic detail, coverage, or depth).
Why does TOPMed use centralized data-generation processes?
The structure is designed to accelerate access to high-quality, standardized multi-omics resources by leveraging centralized TOPMed processes, instead of having many separate labs generate smaller datasets that may be less harmonized.
Are clinical trials allowed under this FOA?
No. The FOA states that clinical trials are not allowed. Applications should focus on observational research, biospecimen-based analyses, omics data generation, data integration, and related discovery work rather than interventional studies.
What are the data sharing expectations?
Broad data sharing is a core expectation. Omics outputs and associated phenotypic data are intended to be deposited into NIH-designated controlled-access repositories, specifically dbGaP and NHLBI's BioData Catalyst (BDC).
What does "controlled access" mean for data sharing?
Controlled access means the data will be made available to qualified investigators under NIH data use and governance rules, rather than being posted with fully open public access.
What repositories are specifically named for data deposition?
The FOA calls out dbGaP (the Database of Genotypes and Phenotypes) and NHLBI's BioData Catalyst (BDC) as controlled-access repositories for omics and associated phenotypic data.
What implications does controlled-access deposition have for applicants?
Applicants need to be prepared for consent, privacy, governance, and data harmonization requirements associated with generating datasets intended for public controlled-access distribution.
Who can apply for this opportunity?
Eligibility is broad and includes many organization types across government, academia, nonprofit, and industry, as well as U.S. and non-U.S. entities.
What government entities are eligible to apply?
Eligible government applicants include state, county, city, township, and special district governments, among others.
Are public housing authorities and independent school districts eligible?
Yes. The FOA explicitly includes public housing authorities and independent school districts among eligible applicants.
What types of academic organizations can apply?
Eligible academic applicants include public and state-controlled universities, private institutions of higher education, and other research-performing organizations.
Can nonprofits apply?
Yes. Nonprofit organizations with or without 501(c)(3) status are included as eligible applicants.
Can for-profit organizations apply?
Yes. For-profit organizations (other than small businesses) are listed as eligible, and small businesses are also listed as eligible.
Are institutions that serve underrepresented communities highlighted?
Yes. The FOA highlights inclusion of organizations that broaden participation across communities and geographies, including HBCUs, Hispanic-serving Institutions, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, and AANAPISIs.
Are tribal governments and tribal organizations eligible?
Yes. Tribal governments and tribal organizations are included among eligible applicants.
Are faith-based and community-based organizations eligible?
Yes. Faith-based and community-based organizations are listed as eligible to apply.
Are U.S. territories and possessions eligible?
Yes. U.S. territories or possessions are included in the eligibility list.
Are non-U.S. (foreign) entities eligible?
Yes. The FOA indicates that non-U.S. (foreign) entities may apply.
Is this opportunity considered a discretionary grant?
Yes. It is described as a discretionary NIH grant opportunity categorized under health research.
Which federal agency and institute are associated with this opportunity?
The opportunity is associated with the National Institutes of Health (NIH), specifically the National Heart, Lung, and Blood Institute (NHLBI), and it is tied to the TOPMed program.
What is the activity code used for this FOA?
The FOA uses the X01 activity code.
What CFDA numbers are linked to this opportunity?
The opportunity is linked to multiple CFDA numbers: 93.233, 93.837, 93.838, 93.839, and 93.840.
When was this opportunity created?
The opportunity was created on June 1, 2022.
What is the listed closing date?
The listed closing date is October 17, 2024.
Is an award ceiling or expected number of awards provided in the summary?
No. Those fields are not specified in the information provided.
What is the intended end product of projects supported by this FOA?
The intended end product is not only a dataset for a single study, but a community resource: large-scale, standardized multi-omics and phenotypic datasets deposited into controlled-access NIH repositories to enable broader mechanism-focused discovery across studies.
How does this FOA address gaps in existing TOPMed resources?
It prioritizes generating integrated genetic and multi-omics data where current TOPMed datasets do not provide enough coverage, depth, population diversity, disease representation, or phenotypic detail to answer important biological questions.
Why is diversity and representation emphasized?
The FOA aligns with TOPMed goals of improving representation so that omics reference resources are relevant across diverse populations, which can strengthen the generalizability and usefulness of resulting datasets.
Browse more opportunities from the same category: Health
Next opportunity: Maintaining Immunity after Immunization (U01 Clinical Trial Not Allowed)
Previous opportunity: National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U19 Clinical Trial Optional)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 22 194
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 22 194) also looked into and applied for these:
| Funding Opportunity |
|---|
| Data Management Coordinating Center for Diagnostic Centers of Excellence (U2C Clinical Trial Not Allowed) Apply for RFA NS 22 051 Funding Number: RFA NS 22 051 Agency: National Institutes of Health Category: Health Funding Amount: $3,000,000 |
| Measures and Methods for Research on Family Caregivers for People Living with Alzheimers Disease and Related Dementias (AD/ADRD) (R21 Clinical Trial Not Allowed) Apply for RFA AG 23 023 Funding Number: RFA AG 23 023 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Measures and Methods for Research on Family Caregivers for People Living with Alzheimers Disease and Related Dementias (AD/ADRD) (R01 Clinical Trial Not Allowed) Apply for RFA AG 23 022 Funding Number: RFA AG 23 022 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pragmatic Clinical Trials in Community Settings to Decrease or Prevent VCID Outcomes, Including in Populations that Experience Health Disparities (U01 Clinical Trial Required) Apply for RFA NS 23 001 Funding Number: RFA NS 23 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional) Apply for PAS 22 196 Funding Number: PAS 22 196 Agency: National Institutes of Health Category: Health Funding Amount: $1,838,436 |
| Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional) Apply for PAS 22 197 Funding Number: PAS 22 197 Agency: National Institutes of Health Category: Health Funding Amount: $1,838,436 |
| Transformative Artificial Intelligence and Machine Learning Based Strategies to Identify Determinants of Exceptional Health and Life Span (R21/R33 Clinical Trial Not Allowed) Apply for RFA AG 23 033 Funding Number: RFA AG 23 033 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Structural Biology of Alzheimer's Disease Related Dementias (ADRDs) Proteinopathies (R01 Clinical Trial Not Allowed) Apply for PAR 22 208 Funding Number: PAR 22 208 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Molecular Dynamics of HIV (R01 Clinical Trial Not Allowed) Apply for RFA AI 22 050 Funding Number: RFA AI 22 050 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed) Apply for RFA TR 22 030 Funding Number: RFA TR 22 030 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Harnessing Technologies to Support Oral Health Promotion and Management Outside the Dental Setting (UG3/UH3 Clinical Trial Required) Apply for RFA DE 23 009 Funding Number: RFA DE 23 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Claude D. Pepper Older Americans Independence Centers (P30 Clinical Trial Optional) Apply for RFA AG 23 017 Funding Number: RFA AG 23 017 Agency: National Institutes of Health Category: Health Funding Amount: $925,000 |
| Impact of the Microbiome-Gut-Brain Axis on Alzheimer's Disease and Alzheimer's Disease-Related Dementias (R01 Clinical Trial Not Allowed) Apply for PAR 22 211 Funding Number: PAR 22 211 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R43/R44 Clinical Trial Optional) Apply for RFA AG 23 029 Funding Number: RFA AG 23 029 Agency: National Institutes of Health Category: Health Funding Amount: $1,838,436 |
| Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed) Apply for PAR 22 170 Funding Number: PAR 22 170 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R41/R42 Clinical Trial Optional) Apply for RFA AG 23 030 Funding Number: RFA AG 23 030 Agency: National Institutes of Health Category: Health Funding Amount: $1,838,436 |
| New Epidemiological Cohort Study among Asian Americans, Native Hawaiians, and Pacific Islanders (AsA-NHPI): Clinical/Community Field Centers (UG3/UH3 - Clinical Trial Not Allowed) Apply for RFA HL 23 015 Funding Number: RFA HL 23 015 Agency: National Institutes of Health Category: Health Funding Amount: $373,000 |
| Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical Trial Optional) Apply for PAR 22 213 Funding Number: PAR 22 213 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| New Epidemiological Cohort Study among Asian Americans, Native Hawaiians, and Pacific Islanders (AsA-NHPI): Coordinating Center (U24 - Clinical Trial Not Allowed) Apply for RFA HL 23 016 Funding Number: RFA HL 23 016 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional) Apply for PAR 22 169 Funding Number: PAR 22 169 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 22 194", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.